Russian MedicineRussian Medicine0869-21062412-9100Eco-Vector4255610.18821/0869-2106-2020-26-2-125-132Review ArticleFulminant diabetes mellitus and concomitant enterovirus infection: a clinical caseSaprinaT. V.<p>MD, PhD, DSc, Professor</p>tvsaprina@gmail.comhttps://orcid.org/0000-0001-9011-8720MusinaN. N.nadiezhda-musina@mail.ruhttps://orcid.org/0000-0001-7148-6739VtorushinS. V.<p>MD, PhD, DSc, Professor</p>wtorushin@rambler.ruhttps://orcid.org/0000-0002-1195-4008Krakhmal’N. V.<p>MD, PhD</p>krakhmal@mail.ruhttps://orcid.org/0000-0002-1909-1681RogovskayaYu. V.<p>MD, PhD</p>mynga@sibmail.comhttps://orcid.org/0000-0001-5553-7831Siberian State Medical UniversityCancer Research Institute, Tomsk National Research Medical CenterCardiology Research Institute, Tomsk National Research Medical Center1908202026212513219082020Copyright © 2020, Eco-Vector2020<p>Fulminant type 1 diabetes mellitus is a subtype of diabetes mellitus. It is characterized by the extremely rapid development of hyperglycemia and ketoacidosis because of the near-total destruction of pancreatic -cells. A clinical case of lethal, type 1, fulminant diabetes mellitus is presented. The patient management strategy and possible causes of the adverse course and outcome of the disease are analyzed.</p>clinical casefulminant diabetes mellitustype 1 diabetes mellitusketoacidosisinfectious myocarditisinsulinслучай из практикифульминантный сахарный диабетсахарный диабет 1 типакетоацидозинфекционный миокардитинсулит[Imagawa A., Hanafusa T., Miyagawa J., Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N. Engl. J. Med. 2000; 342(5): 301–7. Doi: 10.1056/NEJM200002033420501.][Moreau C., Drui D., Arnault-Ouary G., Charbonnel B., Chaillous L., Cariou B. Fulminant type 1 diabetes in Caucasians: a report of three cases. Diabetes Metab. 2008; 34(5): 529–32. Doi: 10.1016/j.diabet.2008.05.003.][Imagawa A., Hanafusa T., Uchigata Y., Kanatsuka A., Kawasaki E., Kobayashi T. et al. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care. 2003; 26(8): 2345–52. Doi: 10.2337/diacare.26.8.2345.][Imagawa A., Hanafusa T. Pathogenesis of fulminant type 1 diabetes. Rev Diabet Stud. 2006; 3(4): 169–77. Doi: 10.1900/RDS.2006.3.169.][Imagawa A., Hanafusa T., Makino H., Miyagawa J.I., Juto P. High titres of IgA antibodies to enterovirus in fulminant type-1 diabetes. Diabetologia. 2005 Feb; 48(2): 290–3. Doi: 10.1007/s00125-004-1624-z.][Tanaka S., Nishida Y., Aida K., Maruyama T., Shimada A., Suzuki M. et al. Enterovirus infection, CXC chemokine ligand 10 (CXCL10), and CXCR3 circuit: a mechanism of accelerated beta-cell failure in fulminant type 1 diabetes. Diabetes. 2009; 58(10): 2285–91. Doi: 10.2337/db09-0091.][Imagawa A., Hanafusa T., Awata T., Ikegami H., Uchigata Y., Osawa H. et al. Report of the Committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012). Diabetes Investig. 2012; 3(6): 536–9. Doi: 10.1111/jdi.12024.][Uto T., Uto K., Teno S., Isono K., Omori Y. A case of fulminant type 1 diabetes mellitus detected after cardiac arrest due to diabetic ketoacidosis. J Japan Diab Soc. 2002; 45(9): 689–93. Doi: 10.11213/tonyobyo1958.45.689.][Shimizu I., Makino H., Imagawa A., Iwahashi H., Uchigata Y., Kanatsuka A., Clinical and Immunogenetic Characteristics of Fulminant Type 1 Diabetes Associated With Pregnancy. J Clin Endocrinol Metab. 2006; 91(2): 471-6. Doi: 10.1210/jc.2005-1943.]